Literature DB >> 30632084

Beyond the Window: Patient Characteristics and Geographic Locations Associated with Late Prenatal Care in Women Eligible for 17-P Preterm Birth Prevention.

Sarahn Wheeler1, Anna DeNoble2, Clara Wynn2, Kristin Weaver2, Geeta Swamy2, Mark Janko3, Paul Lantos3,4.   

Abstract

INTRODUCTION: To reduce the risk of recurrence, women with a history of spontaneous preterm birth (PTB) are recommended to receive 17-hydroxyprogesterone caproate (17-P) injections starting by the 20th week of pregnancy. In women eligible for 17-P, we aimed to identify patient factors and geospatial locations associated with increased risk of presentation beyond 20 weeks gestation.
METHODS: We conducted a secondary analysis of a retrospective cohort study including all women meeting criteria for 17-P within a single academic medical center over a 2-year period. We compared early (< 20 6/7 weeks) with late (> 21 weeks) presenters via demographics, social history, and index pregnancy outcomes using standard and Bayesian statistical models. Geospatial mapping was performed to determine residential areas with high risk for late presentation.
RESULTS: Geocoded address data was available for 351 women in whom the mean gestational age at first visit was 14.9 weeks, and 63 of whom were late presenters (17.9%). Younger maternal age, current smoking, and lack of health insurance were predictors of late presentation with greater than 95% probability. Hispanic ethnicity and black race were associated with higher odds of late presentation with 87 and 69% probability, respectively. The area with the latest gestational age at presentation was located within central Durham City and to the northeast. DISCUSSION: Our study identified patient-level risk factors and geographic locations associated with presentation beyond the recommend window for 17-P initiation. These findings suggest an urgent need for intervention to improve early prenatal care initiation and a target location where such interventions will be most impactful.

Entities:  

Keywords:  17-P; 17-hydroxyprogesterone caproate; Disparity; Preterm birth

Mesh:

Substances:

Year:  2019        PMID: 30632084     DOI: 10.1007/s40615-018-00555-8

Source DB:  PubMed          Journal:  J Racial Ethn Health Disparities        ISSN: 2196-8837


  12 in total

1.  Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor.

Authors:  J W Johnson; K L Austin; G S Jones; G H Davis; T M King
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  Progesterone and preterm birth prevention: translating clinical trials data into clinical practice.

Authors: 
Journal:  Am J Obstet Gynecol       Date:  2012-05       Impact factor: 8.661

3.  Scaling regression inputs by dividing by two standard deviations.

Authors:  Andrew Gelman
Journal:  Stat Med       Date:  2008-07-10       Impact factor: 2.373

4.  Practice bulletin no. 130: prediction and prevention of preterm birth.

Authors: 
Journal:  Obstet Gynecol       Date:  2012-10       Impact factor: 7.661

5.  Impact of 17P usage on NICU admissions in a managed medicaid population--a five-year review.

Authors:  Mary V Mason; Amy Poole-Yaeger; Cathie R Krueger; Kara M House; Brad Lucas
Journal:  Manag Care       Date:  2010-02

6.  Assessment of adherence to guidelines for using progesterone to prevent recurrent preterm birth.

Authors:  Stephen S Crane; Robin Naples; Cindy K Grand; Sarah Friebert; Neil L McNinch; Anand Kantak; Elena Rossi; John McBride
Journal:  J Matern Fetal Neonatal Med       Date:  2015-08-13

7.  Use and attitudes of obstetricians toward 3 high-risk interventions in MFMU Network hospitals.

Authors:  Sabine Zoghbi Bousleiman; Madeline Murguia Rice; Joan Moss; Allison Todd; Monica Rincon; Gail Mallett; Cynthia Milluzzi; Donna Allard; Karen Dorman; Felecia Ortiz; Francee Johnson; Peggy Reed; Susan Tolivaisa
Journal:  Am J Obstet Gynecol       Date:  2015-05-06       Impact factor: 8.661

8.  Maternal factors influencing late entry into prenatal care: a stratified analysis by race or ethnicity and insurance status.

Authors:  Rebecca J Baer; Molly R Altman; Scott P Oltman; Kelli K Ryckman; Christina D Chambers; Larry Rand; Laura L Jelliffe-Pawlowski
Journal:  J Matern Fetal Neonatal Med       Date:  2018-04-22

9.  Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.

Authors:  Paul J Meis; Mark Klebanoff; Elizabeth Thom; Mitchell P Dombrowski; Baha Sibai; Atef H Moawad; Catherine Y Spong; John C Hauth; Menachem Miodovnik; Michael W Varner; Kenneth J Leveno; Steve N Caritis; Jay D Iams; Ronald J Wapner; Deborah Conway; Mary J O'Sullivan; Marshall Carpenter; Brian Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman; Steven Gabbe
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

10.  17-Hydroxyprogesterone caproate (17OHP-C) coverage among eligible women delivering at 2 North Carolina hospitals in 2012 and 2013: A retrospective cohort study.

Authors:  Elizabeth M Stringer; Catherine J Vladutiu; Tracy Manuck; Sarah Verbiest; Arthur Ollendorff; Jeffrey S A Stringer; M Kathryn Menard
Journal:  Am J Obstet Gynecol       Date:  2016-01-29       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.